Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer

J. Schnittert, M.A. Heinrich, P.R. Kuninty, G. Storm, J. Prakash (Corresponding Author)

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)
48 Downloads (Pure)

Abstract

Pancreatic stellate cells (PSCs) are the precursors of cancer-associated fibroblasts (CAFs), which potentiate pancreatic tumor growth and progression. In this study, we investigated whether Lipoxin A4 (LXA4), an endogenous bioactive lipid, can inhibit the differentiation of human PSCs (hPSCs) into CAF-like myofibroblasts and thereby hPSC-induced pro-tumorigenic effects. LXA4 significantly inhibited TGF-β-mediated differentiation of hPSCs by inhibiting pSmad2/3 signalling. Furthermore, treatment with LXA4 abolished the paracrine effects (proliferation and migration of Panc-1 tumor cells) of hPSCs in vitro. These data demonstrated that LXA4 can interrupt pro-tumoral paracrine signalling of hPSCs. Furthermore, LXA4 treatment significant decreased the size and growth rate of 3D-heterospheroids comprised of hPSC and Panc-1 and these effects were exhibited due to inhibition of hPSC-induced collagen1 expression. In vivo, we examined the therapeutic efficacy of LXA4 in a co-injection (Panc-1 and hPSCs) subcutaneous tumor model. Intriguingly, LXA4 significantly abolished the tumor growth (either injected intratumor or intraperitoneally), attributed to a significant reduction in fibrosis, shown with collagen1 expression. Altogether, this study proposes LXA4 as a potent inhibitor for hPSCs which can be applied to reprogram tumor stroma in order to treat pancreatic cancer.
Original languageEnglish
Pages (from-to)247-258
Number of pages12
JournalCancer letters
Volume420
DOIs
Publication statusPublished - 28 Apr 2018

Fingerprint

Pancreatic Neoplasms
Lipids
Neoplasms
Pancreatic Stellate Cells
Growth
Paracrine Communication
lipoxin A4
Myofibroblasts
Fibrosis
Therapeutics
Injections

Keywords

  • UT-Hybrid-D

Cite this

@article{7f8935c442674de88e14972bd8ee6e57,
title = "Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer",
abstract = "Pancreatic stellate cells (PSCs) are the precursors of cancer-associated fibroblasts (CAFs), which potentiate pancreatic tumor growth and progression. In this study, we investigated whether Lipoxin A4 (LXA4), an endogenous bioactive lipid, can inhibit the differentiation of human PSCs (hPSCs) into CAF-like myofibroblasts and thereby hPSC-induced pro-tumorigenic effects. LXA4 significantly inhibited TGF-β-mediated differentiation of hPSCs by inhibiting pSmad2/3 signalling. Furthermore, treatment with LXA4 abolished the paracrine effects (proliferation and migration of Panc-1 tumor cells) of hPSCs in vitro. These data demonstrated that LXA4 can interrupt pro-tumoral paracrine signalling of hPSCs. Furthermore, LXA4 treatment significant decreased the size and growth rate of 3D-heterospheroids comprised of hPSC and Panc-1 and these effects were exhibited due to inhibition of hPSC-induced collagen1 expression. In vivo, we examined the therapeutic efficacy of LXA4 in a co-injection (Panc-1 and hPSCs) subcutaneous tumor model. Intriguingly, LXA4 significantly abolished the tumor growth (either injected intratumor or intraperitoneally), attributed to a significant reduction in fibrosis, shown with collagen1 expression. Altogether, this study proposes LXA4 as a potent inhibitor for hPSCs which can be applied to reprogram tumor stroma in order to treat pancreatic cancer.",
keywords = "UT-Hybrid-D",
author = "J. Schnittert and M.A. Heinrich and P.R. Kuninty and G. Storm and J. Prakash",
note = "Elsevier deal",
year = "2018",
month = "4",
day = "28",
doi = "10.1016/j.canlet.2018.01.072",
language = "English",
volume = "420",
pages = "247--258",
journal = "Cancer letters",
issn = "0304-3835",
publisher = "Elsevier",

}

Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer. / Schnittert, J.; Heinrich, M.A.; Kuninty, P.R. ; Storm, G.; Prakash, J. (Corresponding Author).

In: Cancer letters, Vol. 420, 28.04.2018, p. 247-258.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer

AU - Schnittert, J.

AU - Heinrich, M.A.

AU - Kuninty, P.R.

AU - Storm, G.

AU - Prakash, J.

N1 - Elsevier deal

PY - 2018/4/28

Y1 - 2018/4/28

N2 - Pancreatic stellate cells (PSCs) are the precursors of cancer-associated fibroblasts (CAFs), which potentiate pancreatic tumor growth and progression. In this study, we investigated whether Lipoxin A4 (LXA4), an endogenous bioactive lipid, can inhibit the differentiation of human PSCs (hPSCs) into CAF-like myofibroblasts and thereby hPSC-induced pro-tumorigenic effects. LXA4 significantly inhibited TGF-β-mediated differentiation of hPSCs by inhibiting pSmad2/3 signalling. Furthermore, treatment with LXA4 abolished the paracrine effects (proliferation and migration of Panc-1 tumor cells) of hPSCs in vitro. These data demonstrated that LXA4 can interrupt pro-tumoral paracrine signalling of hPSCs. Furthermore, LXA4 treatment significant decreased the size and growth rate of 3D-heterospheroids comprised of hPSC and Panc-1 and these effects were exhibited due to inhibition of hPSC-induced collagen1 expression. In vivo, we examined the therapeutic efficacy of LXA4 in a co-injection (Panc-1 and hPSCs) subcutaneous tumor model. Intriguingly, LXA4 significantly abolished the tumor growth (either injected intratumor or intraperitoneally), attributed to a significant reduction in fibrosis, shown with collagen1 expression. Altogether, this study proposes LXA4 as a potent inhibitor for hPSCs which can be applied to reprogram tumor stroma in order to treat pancreatic cancer.

AB - Pancreatic stellate cells (PSCs) are the precursors of cancer-associated fibroblasts (CAFs), which potentiate pancreatic tumor growth and progression. In this study, we investigated whether Lipoxin A4 (LXA4), an endogenous bioactive lipid, can inhibit the differentiation of human PSCs (hPSCs) into CAF-like myofibroblasts and thereby hPSC-induced pro-tumorigenic effects. LXA4 significantly inhibited TGF-β-mediated differentiation of hPSCs by inhibiting pSmad2/3 signalling. Furthermore, treatment with LXA4 abolished the paracrine effects (proliferation and migration of Panc-1 tumor cells) of hPSCs in vitro. These data demonstrated that LXA4 can interrupt pro-tumoral paracrine signalling of hPSCs. Furthermore, LXA4 treatment significant decreased the size and growth rate of 3D-heterospheroids comprised of hPSC and Panc-1 and these effects were exhibited due to inhibition of hPSC-induced collagen1 expression. In vivo, we examined the therapeutic efficacy of LXA4 in a co-injection (Panc-1 and hPSCs) subcutaneous tumor model. Intriguingly, LXA4 significantly abolished the tumor growth (either injected intratumor or intraperitoneally), attributed to a significant reduction in fibrosis, shown with collagen1 expression. Altogether, this study proposes LXA4 as a potent inhibitor for hPSCs which can be applied to reprogram tumor stroma in order to treat pancreatic cancer.

KW - UT-Hybrid-D

U2 - 10.1016/j.canlet.2018.01.072

DO - 10.1016/j.canlet.2018.01.072

M3 - Article

VL - 420

SP - 247

EP - 258

JO - Cancer letters

JF - Cancer letters

SN - 0304-3835

ER -